Dasotraline is primarily researched for its potential in treating psychiatric disorders, particularly attention deficit hyperactivity disorder (ADHD) and binge eating disorder (BED). It functions as a dopamine and norepinephrine reuptake inhibitor, which helps regulate mood and attention. In clinical trials, it has shown promise in improving focus, reducing impulsivity, and managing symptoms of ADHD. For binge eating disorder, it may help control compulsive eating behaviors by stabilizing neurotransmitter activity. Its long half-life allows for once-daily dosing, making it a convenient option for patients. However, its use is still under investigation, and further studies are needed to confirm its efficacy and safety.